Research programme: autotaxin inhibitors - TaiwanJ Pharmaceuticals
Latest Information Update: 28 Jun 2023
At a glance
- Originator TaiwanJ Pharmaceuticals
- Class Antifibrotics; Hepatoprotectants
- Mechanism of Action ENPP2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for research development in Fibrosis in Taiwan
- 28 Jun 2023 No recent reports of development identified for research development in Non-alcoholic-steatohepatitis in Taiwan
- 28 May 2019 Early research in Non-alcoholic steatohepatitis in Taiwan (unspecified route) (TaiwanJ Pharmaceuticals pipeline, May 2019)